ArticlePulmonary medicine2026
Survival and Hemodynamic Effects of Parenteral Prostanoids in High-Altitude Group 1 Pulmonary Hypertension: A Retrospective Cohort Study.
Article in Pulmonary medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundIn Latin America, the evidence regarding the use of prostanoids at high altitude in patients with Group 1 pulmonary hypertension (PH-1) is limited. Therefore, it is essential to describe the clinical characteristics and outcomes associated with prostanoid treatment in this population.
methodsThis retrospective study involved patients with PH-1. Hemodynamic and clinical variables were compared before the initiation of prostanoids and during clinical follow-up. Overall survival was analyzed using Kaplan-Meier estimation, with survival rates calculated at 3 and 5 years. The strength of the association for each variable concerning the proposed outcomes was estimated by calculating the odds ratio (OR).
resultsThe study included 55 patients (mean age 34.6 ± 10.3 years), 83.6% women, all receiving triple combination therapy with endothelin receptor antagonists (ERAs), phosphodiesterase Type 5 inhibitors, and parenteral prostacyclin analogues. Idiopathic pulmonary arterial hypertension was present in 62%, and 60% were classified as intermediate risk at baseline. Median time from PH-1 diagnosis to prostacyclin initiation was 8.96 months (IQR 1.88-41.42). At 1 year, complete follow-up data were available for 49 patients. St. George's Respiratory Questionnaire scores improved significantly from 49.0 to 36.5 at 1 year and 31.5 at the last follow-up (p < 0.001). Cardiac index increased from 2.24 to 2.96 L/min/m
conclusionParenteral prostanoids in patients with PH-1 demonstrate improvements in hemodynamic variables during clinical follow-up. A DLCO < 25% and a TAPSE/PASP < 0.10 mm/mmHg were associated with an increased risk of mortality, whereas female sex was identified as a protective factor.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.